The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

The agency added timelines should ... has already been approved by the European Commission (EC) under the brand name Ordspono for r/r FL and diffuse large B-cell lymphoma (DLBCL) after two or ...

The data from the study won't be divulged before it is presented at a future oncology congress, but Roche has said it intends to file for approval of Polivy in previously-untreated DLBCL "as soon ...

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study 1,2 DLBCL—an aggressive disease with a high risk of progression—remains an area of high ...

The approval is based on efficacy and safety data from the phase 3 ECHELON-3 study, which demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) in ...

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study 1,2 DLBCL-an aggressive disease with a high risk of progression-remains an area of high ...